Abstract
We evaluated the effect of angiotensin-converting enzyme inhibition (quinapril) on cardiopulmonary baroreflex sensitivity in 30 patients with uncomplicated myocardial infarction (quinapril group, 15 patients; placebo group, 15 patients) at 5 and 10 days after the onset of myocardial infarction. This study indicates that quinapril improved cardiopulmonary baroreflex and thus reduced sympathetic outflow in patients with acute myocardial infarction.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Baroreflex / drug effects*
-
Baroreflex / physiology
-
Blood Flow Velocity / drug effects
-
Blood Flow Velocity / physiology
-
Central Venous Pressure / drug effects
-
Central Venous Pressure / physiology
-
Female
-
Forearm / blood supply
-
Humans
-
Isoquinolines / administration & dosage
-
Isoquinolines / therapeutic use*
-
Male
-
Middle Aged
-
Myocardial Infarction / blood
-
Myocardial Infarction / drug therapy
-
Myocardial Infarction / physiopathology*
-
Norepinephrine / blood
-
Quinapril
-
Renin / blood
-
Sympathetic Nervous System / drug effects
-
Sympathetic Nervous System / physiopathology*
-
Tetrahydroisoquinolines*
-
Vascular Resistance / drug effects
-
Vascular Resistance / physiology
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Isoquinolines
-
Tetrahydroisoquinolines
-
Renin
-
Quinapril
-
Norepinephrine